TransCode Therapeutics, Inc. Share Price & Technical Analysis
RNAZ · $4.98 (-2.16%)
Healthcare / Biotechnology
$4.98
-2.16%
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic…
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-7% return in Jun, -24% avg return in past 3 year Jun month.
-22% return in 2026, -144% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 42% | 1% | -8% | -10% | -39% | -7% | – | – | – | – | – | – | -22% |
| 25 | 125% | -72% | -75% | -14% | -49% | 15% | 39% | -10% | 14% | 2% | -16% | -27% | -70% |
| 24 | -89% | -2% | -2% | -8% | 193% | -41% | -72% | -8% | 118% | -18% | -25% | -69% | -24% |
| 23 | 15% | -49% | -32% | -4% | -34% | -44% | -4% | -32% | -66% | -28% | -30% | -29% | -338% |
| 22 | -9% | -8% | 33% | -9% | -34% | -32% | 13% | -11% | -8% | -42% | -42% | 57% | -91% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.86M
P/E ratio
—
52W high
$20.99
52W low
$3.82
Volume
20,522
Beta
1.40
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is TransCode Therapeutics, Inc. share price today?
- TransCode Therapeutics, Inc. (RNAZ) last traded around $4.98 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RNAZ have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RNAZ. Download the app for real-time alerts.
- How can I analyze TransCode Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.